$PCVX
Vaxcyte, Inc. Stock $pcvx

$pcvx Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000095017023004654 Filed on February 27, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$26.09M	$23.33M	$73.59M
YoY Change	89.45%	95.71%	72.19%
% of Gross Profit
Research & Development	$58.08M	$40.24M	$169.5M
YoY Change	83.34%	124.54%	116.11%
% of Gross Profit
Depreciation & Amortization	$712.0K	$702.0K	$2.577M
YoY Change	22.34%	52.94%	43.17%
% of Gross Profit
Operating Expenses	$71.19M	$63.58M	$232.3M
YoY Change	81.52%	113.02%	124.03%
Operating Profit	-$71.19M		-$232.3M
YoY Change	81.52%		124.03%
Interest Expense	$10.08M	$7.642M	$2.000K
YoY Change	13334.67%	1937.87%	-71.43%
% of Operating Profit
Other Income/Expense, Net	$10.73M	$925.0K	$8.771M
YoY Change	4465.96%	1.87%	144.11%
Pretax Income	-$60.46M	-$78.05M	-$223.5M
YoY Change	55.09%	173.26%	123.31%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$60.46M	-$78.05M	-$223.5M
YoY Change	55.09%	173.26%	123.31%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.70		-$3.44
Diluted Earnings Per Share	-$0.70	-$0.99	-$3.44
COMMON SHARES
Basic Shares Outstanding	80.03M	78.98M	64.88M
Diluted Shares Outstanding	86.21M		64.88M

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$822.0M	$931.4M	$931.4M
YoY Change	145.65%	278.65%	278.65%
Cash & Equivalents	$380.5M	$834.7M	$834.7M
Short-Term Investments	$441.6M	$96.72M	$96.72M
Other Short-Term Assets	$18.64M	$11.18M	$11.18M
YoY Change	145.79%	7.72%	7.72%
Inventory
Prepaid Expenses		$5.312M
Receivables
Other Receivables
Total Short-Term Assets	$840.7M	$942.6M	$942.6M
YoY Change	145.65%	267.69%	267.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$15.21M	$10.36M	$31.65M
YoY Change	49.98%	30.25%	-11.87%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$127.8M	$26.55M	$26.55M
YoY Change	622.24%	-2.09%	-2.09%
Other Assets	$3.940M	$4.555M	$5.426M
YoY Change	-30.47%	11.4%	9.4%
Total Long-Term Assets	$167.5M	$63.62M	$63.62M
YoY Change	176.87%	-6.42%	-6.42%
TOTAL ASSETS
Total Short-Term Assets	$840.7M	$942.6M	$942.6M
Total Long-Term Assets	$167.5M	$63.62M	$63.62M
Total Assets	$1.008B	$1.006B	$1.006B
YoY Change	150.34%	210.23%	210.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.62M	$9.795M	$9.795M
YoY Change	141.93%	44.94%	44.94%
Accrued Expenses	$18.35M	$15.38M	$30.73M
YoY Change	136.97%	74.97%	39.95%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$52.75M	$40.53M	$40.53M
YoY Change	93.57%	41.12%	41.12%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$7.000K	$9.000K	$12.04M
YoY Change	-92.47%	-90.63%	3.77%
Total Long-Term Liabilities	$7.000K	$9.000K	$12.04M
YoY Change	-92.47%	-90.63%	3.77%
TOTAL LIABILITIES
Total Short-Term Liabilities	$52.75M	$40.53M	$40.53M
Total Long-Term Liabilities	$7.000K	$9.000K	$12.04M
Total Liabilities	$63.39M	$52.57M	$52.57M
YoY Change	46.83%	30.37%	30.37%
SHAREHOLDERS EQUITY
Retained Earnings	-$582.6M	-$522.1M
YoY Change	72.55%	74.83%
Common Stock	$1.527B	$1.476B
YoY Change	118.81%	153.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$944.8M	$953.6M	$953.6M
YoY Change
Total Liabilities & Shareholders Equity	$1.008B	$1.006B	$1.006B
YoY Change	150.34%	210.23%	210.23%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$60.46M	-$78.05M	-$223.5M
YoY Change	55.09%	173.26%	123.31%
Depreciation, Depletion And Amortization	$712.0K	$702.0K	$2.577M
YoY Change	22.34%	52.94%	43.17%
Cash From Operating Activities	-$47.69M	-$65.22M	-$170.6M
YoY Change	72.15%	27.65%	40.53%
INVESTING ACTIVITIES
Capital Expenditures	$5.609M	$1.147M	$5.848M
YoY Change	92.09%	-183.0%	-10.79%
Acquisitions
YoY Change
Other Investing Activities	-$442.5M	-$34.80M	$80.43M
YoY Change	-941.46%	-2477.39%	-139.09%
Cash From Investing Activities	-$448.1M	-$35.95M	$74.59M
YoY Change	-1002.23%	-43943.9%	-135.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$97.30M
YoY Change			600.19%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	41.56M	656.6M	861.5M
YoY Change	-62.56%	7400.95%	4741.24%
NET CHANGE
Cash From Operating Activities	-47.69M	-65.22M	-170.6M
Cash From Investing Activities	-448.1M	-35.95M	74.59M
Cash From Financing Activities	41.56M	656.6M	861.5M
Net Change In Cash	-454.2M	555.5M	765.7M
YoY Change	-442.14%	-1414.48%	-342.04%
FREE CASH FLOW
Cash From Operating Activities	-$47.69M	-$65.22M	-$170.6M
Capital Expenditures	$5.609M	$1.147M	$5.848M
Free Cash Flow	-$53.30M	-$66.37M	-$176.4M
YoY Change	74.05%	33.51%	37.9%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001649094
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.593
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-39323
CY2022	dei	Entity Registrant Name EntityRegistrantName	VAXCYTE, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-4233385
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	825 Industrial Road
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	San Carlos
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94070ca
CY2022	dei	City Area Code CityAreaCode	650
CY2022	dei	Local Phone Number LocalPhoneNumber	837-0111
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2022	dei	Trading Symbol TradingSymbol	PCVX
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	1100000000
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	80033727
CY2022	dei	Auditor Firm AuditorFirmId	34
CY2022	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2022	dei	Auditor Location AuditorLocation	San Francisco, California
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	834657000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	68985000
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	96719000
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	176985000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11179000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10378000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	942555000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	256348000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10360000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7954000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	21288000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	27958000
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	26549000
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	27117000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	871000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	871000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4555000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4089000
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	63623000
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	67989000
CY2022Q4	us-gaap	Assets Assets	1006178000
CY2021Q4	us-gaap	Assets Assets	324337000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9795000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6758000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1180000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3455000
CY2022Q4	pcvx	Accrued Manufacturing Expenses AccruedManufacturingExpenses	8265000
CY2021Q4	pcvx	Accrued Manufacturing Expenses AccruedManufacturingExpenses	4440000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15375000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8787000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5910000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5276000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	40525000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	28716000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12031000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11507000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	96000
CY2022Q4	us-gaap	Liabilities Liabilities	52565000
CY2021Q4	us-gaap	Liabilities Liabilities	40319000
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	79470670
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	79470670
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53031978
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53031978
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	82000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	56000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1476018000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	582844000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-361000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-241000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-522126000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-298641000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	953613000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	284018000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1006178000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	324337000
CY2022	pcvx	Research And Development Expense To Related Party ResearchAndDevelopmentExpenseToRelatedParty	0
CY2021	pcvx	Research And Development Expense To Related Party ResearchAndDevelopmentExpenseToRelatedParty	2359000
CY2020	pcvx	Research And Development Expense To Related Party ResearchAndDevelopmentExpenseToRelatedParty	1331000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	169451000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	78411000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	73564000
CY2022	pcvx	Acquired Manufacturing Rights AcquiredManufacturingRights	22995000
CY2021	pcvx	Acquired Manufacturing Rights AcquiredManufacturingRights	0
CY2020	pcvx	Acquired Manufacturing Rights AcquiredManufacturingRights	0
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	39810000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-89217000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-89217000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25259000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16017000
CY2022	us-gaap	Operating Expenses OperatingExpenses	232256000
CY2021	us-gaap	Operating Expenses OperatingExpenses	103670000
CY2020	us-gaap	Operating Expenses OperatingExpenses	89581000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-232256000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-103670000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-89581000
CY2022	us-gaap	Interest Expense InterestExpense	2000
CY2021	us-gaap	Interest Expense InterestExpense	7000
CY2020	us-gaap	Interest Expense InterestExpense	7000
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	8356000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	344000
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	244000
CY2022	pcvx	Grant Income GrantIncome	1931000
CY2021	pcvx	Grant Income GrantIncome	1585000
CY2020	pcvx	Grant Income GrantIncome	2478000
CY2022	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0
CY2021	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	2000
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-44000
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-0
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1470000
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1669000
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2351000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8771000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3593000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	364000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-223485000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-100077000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-89217000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.44
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.44
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.93
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.93
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.02
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.02
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	64877988
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	64877988
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51922108
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51922108
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29545810
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29545810
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-223485000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-100077000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-120000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-241000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-223605000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-100318000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-106373000
CY2020	pcvx	Temporary Equity Conversion Of Preferred Stock Value TemporaryEquityConversionOfPreferredStockValue	270190000
CY2020	pcvx	Adjustments To Additional Paid In Capital Warrant Liability Write Off AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff	629000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	264007000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	635000
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	374000
CY2020	pcvx	Adjustments To Additional Paid In Capital Vesting Of Early Exercised Stock Options AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions	164000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5434000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-89217000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	345843000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3012000
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	10001000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	13847000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	888000
CY2021	pcvx	Adjustments To Additional Paid In Capital Vesting Of Early Exercised Stock Options AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions	16000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10729000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-241000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-100077000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	284018000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4895000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	45814000
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	759181000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1033000
CY2022	pcvx	Release Of Restricted Stock Units Value ReleaseOfRestrictedStockUnitsValue	861000
CY2022	pcvx	Adjustments To Additional Paid In Capital Vesting Of Early Exercised Stock Options AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions	8000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23650000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-120000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-223485000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	953613000
CY2022	us-gaap	Profit Loss ProfitLoss	-223485000
CY2021	us-gaap	Profit Loss ProfitLoss	-100077000
CY2020	us-gaap	Profit Loss ProfitLoss	-89217000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2577000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1800000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1405000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	23650000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	10729000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	5434000
CY2022	pcvx	Non Cash Payments For Acquire Manufacturing Rights NonCashPaymentsForAcquireManufacturingRights	7995000
CY2021	pcvx	Non Cash Payments For Acquire Manufacturing Rights NonCashPaymentsForAcquireManufacturingRights	0
CY2020	pcvx	Non Cash Payments For Acquire Manufacturing Rights NonCashPaymentsForAcquireManufacturingRights	0
CY2022	pcvx	Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liabilities ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities	0
CY2021	pcvx	Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liabilities ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities	0
CY2020	pcvx	Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liabilities ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities	-179000
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-44000
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-97000
CY2020	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-34000
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	213000
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	267000
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	6619000
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1657000
CY2020	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	0
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	947000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1406000
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-433000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7369000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	58000
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	465000
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	3539000
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	75000
CY2022	pcvx	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-1151000
CY2021	pcvx	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	12856000
CY2020	pcvx	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	0
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2896000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-12470000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	26102000
CY2022	pcvx	Increase Decrease In Accrued Compensation IncreaseDecreaseInAccruedCompensation	-2275000
CY2021	pcvx	Increase Decrease In Accrued Compensation IncreaseDecreaseInAccruedCompensation	3170000
CY2020	pcvx	Increase Decrease In Accrued Compensation IncreaseDecreaseInAccruedCompensation	-130000
CY2022	pcvx	Increase Decrease In Accrued Manufacturing Expenses IncreaseDecreaseInAccruedManufacturingExpenses	3826000
CY2021	pcvx	Increase Decrease In Accrued Manufacturing Expenses IncreaseDecreaseInAccruedManufacturingExpenses	-8572000
CY2020	pcvx	Increase Decrease In Accrued Manufacturing Expenses IncreaseDecreaseInAccruedManufacturingExpenses	7235000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	7171000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4631000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2207000
CY2022	pcvx	Increase Decrease In Deferred Rent And Other Long Term Liabilities IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities	0
CY2021	pcvx	Increase Decrease In Deferred Rent And Other Long Term Liabilities IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities	0
CY2020	pcvx	Increase Decrease In Deferred Rent And Other Long Term Liabilities IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities	-11000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-170597000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-121393000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-46628000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5848000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6555000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1155000
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	102745000
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	336341000
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	168691000
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	100500000
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	0
CY2022	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	14480000
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	30062000
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	7000
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	26000
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	50000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	74585000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-212308000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1105000
CY2022	pcvx	Payments Of Capital Lease Obligations PaymentsOfCapitalLeaseObligations	0
CY2021	pcvx	Payments Of Capital Lease Obligations PaymentsOfCapitalLeaseObligations	0
CY2020	pcvx	Payments Of Capital Lease Obligations PaymentsOfCapitalLeaseObligations	61000
CY2022	pcvx	Proceeds From Initial Public Offering Net Of Underwriters Commissions And Discounts ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts	0
CY2021	pcvx	Proceeds From Initial Public Offering Net Of Underwriters Commissions And Discounts ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts	0
CY2020	pcvx	Proceeds From Initial Public Offering Net Of Underwriters Commissions And Discounts ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts	264007000
CY2022	pcvx	Proceeds From Issuance Of Common Stock And Pre Funded Warrants From Follow On Offerings Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts	759181000
CY2021	pcvx	Proceeds From Issuance Of Common Stock And Pre Funded Warrants From Follow On Offerings Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts	0
CY2020	pcvx	Proceeds From Issuance Of Common Stock And Pre Funded Warrants From Follow On Offerings Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts	0
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	97299000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13896000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2022	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0
CY2021	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0
CY2020	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	109879000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4895000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3012000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	635000
CY2022	pcvx	Proceeds From Issuance Of Common Stock Related To Early Exercised Stock Options ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions	0
CY2021	pcvx	Proceeds From Issuance Of Common Stock Related To Early Exercised Stock Options ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions	0
CY2020	pcvx	Proceeds From Issuance Of Common Stock Related To Early Exercised Stock Options ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions	36000
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1033000
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	888000
CY2020	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	374000
CY2022	pcvx	Release Of Restricted Stock Units Value ReleaseOfRestrictedStockUnitsValue	861000
CY2021	pcvx	Release Of Restricted Stock Units Value ReleaseOfRestrictedStockUnitsValue	0
CY2020	pcvx	Release Of Restricted Stock Units Value ReleaseOfRestrictedStockUnitsValue	0
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	861547000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17796000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	374870000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	137000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-439000
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	87000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	765672000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-316344000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	327224000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69856000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	386200000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58976000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	835528000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69856000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	386200000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	2000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	7000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	7000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	110000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	766000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	494000
CY2022	pcvx	Issuance Of Common Stock For Acquired Manufacturing Rights IssuanceOfCommonStockForAcquiredManufacturingRights	7995000
CY2021	pcvx	Issuance Of Common Stock For Acquired Manufacturing Rights IssuanceOfCommonStockForAcquiredManufacturingRights	0
CY2020	pcvx	Issuance Of Common Stock For Acquired Manufacturing Rights IssuanceOfCommonStockForAcquiredManufacturingRights	0
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0
CY2021	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0
CY2020	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	270190000
CY2022	us-gaap	Stock Issued1 StockIssued1	0
CY2021	us-gaap	Stock Issued1 StockIssued1	10000000
CY2020	us-gaap	Stock Issued1 StockIssued1	0
CY2022	pcvx	Deferred Offering Costs Included In Accounts Payable And Accrued Expenses DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses	0
CY2021	pcvx	Deferred Offering Costs Included In Accounts Payable And Accrued Expenses DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses	0
CY2020	pcvx	Deferred Offering Costs Included In Accounts Payable And Accrued Expenses DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses	134000
CY2020Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	one-for-1.6870
CY2020Q2	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	264000000.0
CY2020Q2	pcvx	Payments Of Underwriting Discounts And Commissions PaymentsOfUnderwritingDiscountsAndCommissions	20100000
CY2020Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3400000
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities at the date of the financial statements. On an ongoing basis, we evaluate our estimates and assumptions, including those related to stock-based compensation expense, accruals for certain research and development costs, the incremental borrowing rate, the valuation of deferred tax assets and income</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">taxes. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Management bases our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Financial instruments that potentially subject us to a concentration of credit risk consist primarily of cash and cash equivalents and investments. We invest in money market funds, U.S. Treasury securities, U.S. government agency securities, corporate debt, commercial paper and asset-backed securities. We maintain bank deposits in federally insured financial institutions and these deposits may exceed federally insured limits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash and issuers of investments to the extent recorded on the balance sheets. Our investment policy limits investments to money market funds, certain types of debt securities issued by the U.S. Government and its agencies, corporate debt, commercial paper and asset-backed securities, and places restrictions on the credit ratings, maturities and concentration by type and issuer. We have not experienced any significant losses on our deposits of cash, cash equivalents or investments.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">We are subject to supplier concentration risk from our suppliers. Although we are working to establish secondary sources of supply, we currently source several of our critical raw materials from single source suppliers. We also use one contract manufacturing organization (“CMO”), Lonza Ltd. (“Lonza”), to handle most of our manufacturing activities for our VAX-24 and VAX-31 programs. If we were to experience disruptions in raw materials supplied by our suppliers, or in manufacturing activities at Lonza, we may experience significant delays in our product development timelines and may incur substantial costs to secure alternative sources of raw materials or manufacturing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Our future results of operations involve a number of other risks and uncertainties. Factors that could affect our future operating results and cause actual results to vary materially from expectations include, but are not limited to: our early stages of clinical vaccine development; our ability to advance vaccine candidates into, and successfully complete, clinical trials on the timelines we project; our ability to adequately demonstrate sufficient safety and immunogenicity or efficacy of our vaccine candidates; our ability to enroll subjects in our ongoing and future clinical trials; our ability to successfully manufacture and supply our vaccine candidates for clinical trials; our ability to obtain additional capital to finance our operations; our ability to obtain, maintain and protect our intellectual property rights; developments relating to our competitors and our industry, including competing vaccine candidates; general and market conditions; and other risks and uncertainties, including those more fully described in the “Risk Factors” section of this Annual Report on Form 10-K.</span></p>
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	834657000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	68985000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	386200000
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	871000
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	871000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	835528000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69856000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	386200000
CY2022	pcvx	Number Of Finance Lease NumberOfFinanceLease	0
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	200000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3532000
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	300000
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	96719000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	26549000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	123268000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	16477000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11502000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6117000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3548000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10360000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7954000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2600000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1800000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1400000
CY2022Q4	pcvx	Clinical Studies ClinicalStudies	1518000
CY2021Q4	pcvx	Clinical Studies ClinicalStudies	453000
CY2022Q4	pcvx	Other Research And Development Liabilities Current OtherResearchAndDevelopmentLiabilitiesCurrent	12446000
CY2021Q4	pcvx	Other Research And Development Liabilities Current OtherResearchAndDevelopmentLiabilitiesCurrent	4676000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1411000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3658000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15375000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8787000
CY2022Q4	pcvx	Accrued Manufacturing Rights Expenses AccruedManufacturingRightsExpenses	5000000.0
CY2021Q4	pcvx	Accrued Manufacturing Rights Expenses AccruedManufacturingRightsExpenses	0
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	5374000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	924000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	21288000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	27958000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5910000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5276000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12031000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11507000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	17941000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	16783000
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y9M10D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y9M
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.076
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.075
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6684000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6850000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	7022000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	20556000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2615000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	17941000
CY2021Q4	pcvx	Lessee Operating Lease Liability Payments Net Of Lease Incentives Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsNetOfLeaseIncentivesRemainderOfFiscalYear	105000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6639000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6805000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	6976000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	20315000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	16783000
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	7900000
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	3200000
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	700000
CY2021Q2	pcvx	Development And Manufacturing Services Agreement Payments In Equity DevelopmentAndManufacturingServicesAgreementPaymentsInEquity	10000000.0
CY2022Q4	pcvx	Noncancelable Purchase Commitments Due In One Year NoncancelablePurchaseCommitmentsDueInOneYear	123099000
CY2022Q4	pcvx	Noncancelable Purchase Commitments Due In Second Year And Thereafter NoncancelablePurchaseCommitmentsDueInSecondYearAndThereafter	2471000
CY2022Q4	pcvx	Non Cancelable Purchase Commitments NonCancelablePurchaseCommitments	125570000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	79470670
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	79470670
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53031978
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53031978
CY2022	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0
CY2021	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0
CY2022	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Each share of common stock is entitled to one vote.
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	36710
CY2022	pcvx	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Cancelled ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueCancelled	24320
CY2022	pcvx	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted	26250
CY2022Q1	pcvx	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right Exercised ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised	0.001
CY2022Q4	pcvx	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right Exercised ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised	0.001
CY2022Q1	pcvx	Increase Or Decrease Of Pre Funded Warrant Percentage Not Exceed IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed	0.1999
CY2022Q4	pcvx	Increase Or Decrease Of Pre Funded Warrant Percentage Not Exceed IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed	0.1999
CY2022Q4	pcvx	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right Exercised ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised	0
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2020Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	0.25
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2020Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	0.25
CY2022Q4	pcvx	Early Exercised Stock Options EarlyExercisedStockOptions	3705
CY2021Q4	pcvx	Early Exercised Stock Options EarlyExercisedStockOptions	7410
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	36710
CY2022	pcvx	Number Of Options Exercised Excludes Options Exercised From Npln NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln	1153285
CY2021	pcvx	Number Of Options Exercised Excludes Options Exercised From Npln NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln	926514
CY2020	pcvx	Number Of Options Exercised Excludes Options Exercised From Npln NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln	358264
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.25
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.25
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.88
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	18.88
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	14.65
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.62
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	34000000.0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	18900000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	7800000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	581047
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	79229
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	24790
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	45052
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	456766
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested	26700
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.781
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.851
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.810
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.841
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.812
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.941
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.016
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.044
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.005
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.013
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.003
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.014
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	87700000
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y10M24D
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.015
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.022
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-223485000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-100077000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-89217000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	64877988
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	64877988
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51922108
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51922108
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29545810
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29545810
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.44
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.44
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.93
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.93
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.02
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.02
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8322210
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5423793
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5276418
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.008
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.008
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.011
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.006
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.213
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.230
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.221
CY2022	pcvx	Section162 M Limitation Section162MLimitation	0.018
CY2021	pcvx	Section162 M Limitation Section162MLimitation	-0.011
CY2020	pcvx	Section162 M Limitation Section162MLimitation	-0.001
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	111555000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	85574000
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1062000
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1700000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	1103000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	2174000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	5436000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2865000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	32873000
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2984000
CY2022Q4	pcvx	Deferred Tax Assets Tax Accrued Manufacturing Expenses DeferredTaxAssetsTaxAccruedManufacturingExpenses	2063000
CY2021Q4	pcvx	Deferred Tax Assets Tax Accrued Manufacturing Expenses DeferredTaxAssetsTaxAccruedManufacturingExpenses	1006000
CY2022Q4	pcvx	Lease Liability LeaseLiability	5358000
CY2021Q4	pcvx	Lease Liability LeaseLiability	6674000
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	6867000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4474000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1956000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	170791000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	104934000
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	6357000
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	8349000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	6357000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	8349000
CY2022Q4	pcvx	Deferred Tax Assets Liabilities Net Before Valuation Allowance DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance	164433000
CY2021Q4	pcvx	Deferred Tax Assets Liabilities Net Before Valuation Allowance DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance	96585000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	164433000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	96585000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1800000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	900000
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	924000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	393000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	271000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	876000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	461000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	287000
CY2022	pcvx	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	-46000
CY2021	pcvx	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	70000
CY2020	pcvx	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	-165000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1754000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	924000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	393000

Files In Submission

Name	View Source	Status
pcvx-20221231_cal.xml	Edgar Link	unprocessable
0000950170-23-004654-index-headers.html	Edgar Link	pending
0000950170-23-004654-index.html	Edgar Link	pending
0000950170-23-004654.txt	Edgar Link	pending
0000950170-23-004654-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img123395336_0.jpg	Edgar Link	pending
img127089420_0.jpg	Edgar Link	pending
img127089420_1.jpg	Edgar Link	pending
img127089420_2.jpg	Edgar Link	pending
img127089420_3.jpg	Edgar Link	pending
img127089420_4.jpg	Edgar Link	pending
img127089420_5.jpg	Edgar Link	pending
img127089420_6.jpg	Edgar Link	pending
img151100966_0.jpg	Edgar Link	pending
img70551829_0.jpg	Edgar Link	pending
img70551829_1.jpg	Edgar Link	pending
img70551829_10.jpg	Edgar Link	pending
img70551829_11.jpg	Edgar Link	pending
img70551829_12.jpg	Edgar Link	pending
img70551829_13.jpg	Edgar Link	pending
img70551829_14.jpg	Edgar Link	pending
img70551829_15.jpg	Edgar Link	pending
img70551829_16.jpg	Edgar Link	pending
img70551829_17.jpg	Edgar Link	pending
img70551829_18.jpg	Edgar Link	pending
img70551829_19.jpg	Edgar Link	pending
img70551829_2.jpg	Edgar Link	pending
img70551829_20.jpg	Edgar Link	pending
img70551829_21.jpg	Edgar Link	pending
img70551829_22.jpg	Edgar Link	pending
img70551829_23.jpg	Edgar Link	pending
img70551829_3.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
img70551829_4.jpg	Edgar Link	pending
img70551829_5.jpg	Edgar Link	pending
img70551829_6.jpg	Edgar Link	pending
img70551829_7.jpg	Edgar Link	pending
img70551829_8.jpg	Edgar Link	pending
img70551829_9.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pcvx-20221231.htm	Edgar Link	pending
pcvx-20221231.xsd	Edgar Link	pending
pcvx-ex10_11.htm	Edgar Link	pending
pcvx-ex10_15.htm	Edgar Link	pending
pcvx-ex10_17.htm	Edgar Link	pending
pcvx-ex10_19.htm	Edgar Link	pending
pcvx-ex10_20.htm	Edgar Link	pending
pcvx-ex23_1.htm	Edgar Link	pending
pcvx-ex31_1.htm	Edgar Link	pending
pcvx-ex31_2.htm	Edgar Link	pending
pcvx-ex32_1.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
pcvx-20221231_def.xml	Edgar Link	unprocessable
pcvx-20221231_lab.xml	Edgar Link	unprocessable
pcvx-20221231_pre.xml	Edgar Link	unprocessable
pcvx-20221231_htm.xml	Edgar Link	completed
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PCVX
Vaxcyte, Inc. Stock $pcvx

2023 Q1 Form 10-K Financial Statement

#000095017023004654 Filed on February 27, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCVX Vaxcyte, Inc. Stock $pcvx

2023 Q1 Form 10-K Financial Statement

#000095017023004654 Filed on February 27, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCVX
Vaxcyte, Inc. Stock $pcvx